Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience's anti-VISTA mAb for further clinical development
Hummingbird Bioscience stands to receive up to USD 290 million in upfront and milestone payments, plus royalties, from Percheron Therapeutics
Percheron Therapeutics aims to commence phase II clinical development of HMBD-002 in CY2026
SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for hard-to-treat diseases, today announced that it has granted Percheron Therapeutics Limited (ASX: PER) an exclusive worldwide license to develop, manufacture, and commercialize HMBD-002 in all territories and indications. Under the terms of the agreement, Hummingbird Bioscience will be eligible to receive up to USD 290 million in upfront and milestone payments, plus royalties on net sales.
HMBD-002 is a monoclonal antibody therapy targeting VISTA, a novel checkpoint involved in the body's immune response to cancer. HMBD-002 has successfully completed a phase I clinical trial in the United States, under an Investigational New Drug application with the US Food and Drug Administration, which showed the drug to be pharmacologically active and generally safe and well-tolerated. Percheron Therapeutics aims to continue clinical development of HMBD-002 in CY2026.
'Given the potential benefits of VISTA blockade in multiple cancers that have strong evidence of VISTA-mediated immune suppression, HMBD-002 is a scientifically compelling asset for both monotherapy and combination approaches. We are pleased to have Percheron Therapeutics continue the clinical development of HMBD-002,' said Piers Ingram, PhD, co-founder and Chief Executive Officer of Hummingbird Bioscience. 'We have confidence in the potential clinical benefit of HMBD-002 and in Percheron's ability to successfully progress HMBD-002 through the clinic.'
'Hummingbird Bioscience lies at the cutting edge of novel drug design, and we are delighted to partner with them to take forward this very promising drug candidate,' said Dr. James Garner, Chief Executive Officer of Percheron Therapeutics. 'We selected HMBD-002 out of more than a hundred individual drug candidates from more than seventy companies, and we very much hope that this exciting program can bring meaningful benefit to patients confronting the enormous challenge of a cancer diagnosis.'
About HMBD-002 HMBD-002 is a novel anti-VISTA neutralizing antibody, and the only IgG4 isotype anti-VISTA antibody currently in development. HMBD-002 was engineered to bind to VISTA at a specific site that is predicted to be essential for ligand binding and function, thus inhibiting VISTA and neutralizing its immunosuppressive activity without depleting VISTA-expressing cells that play many important roles in the immune system.
About Hummingbird Bioscience
Hummingbird Bioscience is a biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases. Hummingbird Bioscience's computational and systems biology technologies have generated a pipeline of innovative clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit www.hummingbirdbioscience.com, and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube.
About Percheron Therapeutics Limited
Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialization of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well-tolerated. For more information, please contact info@PercheronTx.com.
CONTACT: Hummingbird Bioscience Media Contact: Crystal Ho c.ho@hummingbirdbio.com media@hummingbirdbio.com +65 6979 5580 Hummingbird Bioscience Investor Contact: investors@hummingbirdbio.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
14 minutes ago
- Washington Post
Avoiding your boss? In Japan, you can hire someone to quit your job for you.
TOKYO — Shota Shimizu slid on his headset and dialed the human resources department at his client's employer, a nursing care company. The client wanted to quit her job, and Shimizu was doing it for her. 'There was a mismatch between her expectations and the reality of the job,' Shimizu told the HR representative. 'She still has her uniform and locker key, and will return them by mail. Can we confirm your mailing address?'
Associated Press
16 minutes ago
- Associated Press
WuXi XDC Announces the Mechanical Completion of its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing
SHANGHAI and SINGAPORE, July 1, 2025 /PRNewswire/ -- On June 30, WuXi XDC Cayman Inc. ('WuXi XDC', stock code: a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announced that the mechanical completion of its manufacturing site at Tuas Biomedical Park in Singapore has been successfully achieved. This milestone signifies that this manufacturing site, spanning approximately 25,000 square meters, will now officially transition into the facility C&Q (Commissioning and Qualification) stage. The Singapore site is expected to commence operations by the end of 2025 and Good Manufacturing Practice (GMP) manufacturing in 2026. Upon that, the site will offer comprehensive production capabilities from the preclinical stage to commercialization. As a critical component of WuXi XDC's global strategy, the Singapore site has demonstrated exceptional progress, adhering to the perfect execution and the 'WuXi Speed' to provide customers with agile and flexible end-to-end CRDMO services. According to current capacity plan, the site is anticipated to create more than 500 job opportunities and over 100 people have joined our company so far. Dr. Jimmy Li, CEO of WuXi XDC, stated, " The rapid mechanical completion of our Singapore site marks a critical pillar in our 'Global Dual-Sourcing' strategy. This global site will form a worldwide network alongside our Wuxi, Changzhou, and Shanghai sites, delivering end-to-end CRDMO services to global customers. This accomplishment showcases the full support of the partners for the construction of Singapore site, our deep understanding of global market demands, our ability to respond swiftly and the robust execution capabilities of our team. Looking ahead, we remain committed to advancing our one-stop model and global supply network, collaborating with global partners to promote the diversified and sustainable development of bioconjugates.' The Singapore site serves as a world-class, one-stop bioconjugates manufacturing center, integrating antibody intermediates, drug substance (DS), and drug products (DP). It strictly adheres to international certification standards and utilizes an advanced modular factory design. Key features include state-of-the-art antibody intermediates production lines, bioconjugate DS and DP production lines, MSAT lab, quality control, intelligent warehousing, and other utility support areas. Equipped with cutting-edge isolator filling lines, fully automated material transfer systems, and digital production management systems, the Singapore site supports multi-level demands ranging from small-scale clinical supplies to large-scale commercial manufacturing, including up to 2,000 liters per batch of mAb/DS, and 8 million vials of DP per year. These capabilities ensure the efficient advancement of projects across various stages while maintaining adherence to the highest quality standards. The Singapore site will be operated under the highest international quality assurance standards, fully complying with Good Manufacturing Practice (GMP) regulations established by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and China's National Medical Products Administration (NMPA). This ensures comprehensive compliance throughout the production process, from antibody intermediates and DS to DP, enabling seamless product release globally. Additionally, the site incorporates environmentally friendly practices, utilizing certified eco-friendly products and implementing strict recycling and waste disposal systems to promote sustainability and enhance the company's ESG management level. About WuXi XDC WuXi XDC Cayman Inc. (stock code: is a globally recognized contract research, development, and manufacturing organization (CRDMO) specializing in bioconjugates. The company offers a wide range of innovative conjugation and payload-linker technologies to facilitate the development of next-generation antibody-drug conjugates (ADCs). Focused on early-stage research and development of ADCs and other bioconjugates, WuXi XDC offers comprehensive one-stop services from clinical to commercial manufacturing. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: WuXi XDC Contacts Investor: [email protected] Media: [email protected] BD: [email protected] View original content: SOURCE WuXi XDC
New York Times
21 minutes ago
- New York Times
China Bans Some Portable Batteries From Flights as Safety Concerns Grow
Travelers in China have been caught off guard in recent days when they arrived at airports to be told they could not bring certain portable batteries aboard their flights. The country's aviation regulator has implemented an emergency ban on some portable batteries aboard flights. The ban, which went into effect Saturday after just two days' notice, came as the regulator warned of growing risks to the aviation industry from batteries, millions of which have been recently recalled. Airlines and governments around the world have tightened regulations on the use of portable batteries on flights this year. But while other airlines have largely issued guidelines on the in-flight use and storage of portable batteries, China's order prohibits passengers from taking some batteries on board planes altogether. The change has caused confusion and consternation among travelers, with some complaining that they had been forced to discard their portable batteries, an increasingly common accessory in modern life, while traveling. The notice of the ban, issued by China's Civil Aviation Administration on Thursday, stated that portable batteries that were not clearly marked as having a Chinese safety certification would not be allowed on flights. Batteries that had been recalled were also prohibited. The aviation authority said the batteries posed a safety risk, citing recent recalls of the devices by manufacturers and episodes of portable batteries catching fire on board planes. China's market regulator has also suspended or revoked the certifications of a number of portable battery and battery cell manufacturers, the aviation authority said. These factors 'demonstrate that portable batteries carried by travelers contain hidden safety and quality dangers, and the risks they pose to the safe operation of civil aviation continues to grow,' the notice said. In past weeks, two major Chinese battery companies have recalled millions of power banks in China and the United States, citing problems with lithium-ion battery cells made by suppliers. In June, Anker, one of the world's largest manufacturers of the batteries, issued a recall for more than one million power banks sold in the United States because it said the lithium-ion battery inside could pose a fire risk. Later that month, the company recalled seven models in China, totaling about 700,000 batteries, according to local news media. Anker then issued a global voluntary recall for another five models, saying that it had identified a potential issue with lithium-ion battery cells provided by a vendor, which it did not name. Romoss, another Chinese battery maker, in June recalled three models of batteries, totaling nearly 500,000 products, because of an issue with their supplier-provided battery cells.
